1.
Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review
He X, Ran N, Wang T, Shao Z
Medicine. 2022;101(50):e32345
Abstract
BACKGROUND To systematically evaluate the clinical efficacy, drug safety and health-related quality of life (HRQoL) of Romiplostim in adult and child immune thrombocytopenia (ITP) patients. METHODS PubMed, EMBASE and Cohrane library databases were searched for all randomized controlled trials published until 2022, and the Review Manager 5.3 was used for meta-analysis. RESULTS A total of 9 randomized controlled trials were included in this study. The results of meta-analysis showed that the total platelet response rate and long-term platelet response rate in treatment group were significantly higher than those in control group (P<0.05). There was no statistical significance in the side effects, serious side effects, bleeding events and serious bleeding events between 2 groups (P>0.05). Compared with control group, the HRQoL in ITP adults and children, and parents of ITP children had no statistical significance (P>0.05). CONCLUSION Romiplostim has a certain clinical efficacy in ITP adults and children, and relatively small adverse drug reactions. The improvement of Romiplostim on HRQoL in ITP adults and children is not clear.
2.
A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease
Zaidi AU, Glaros AK, Lee S, Wang T, Bhojwani R, Morris E, Donohue B, Paulose J, Iorga ŞR, Nellesen D
Orphanet journal of rare diseases. 2021;16(1):460
Abstract
BACKGROUND AND PURPOSE Sickle cell disease (SCD) is a collection of rare inherited blood disorders affecting approximately 100,000 people in the U.S. and 20-25 million people globally. Individuals with SCD experience recurrent episodes of severe and unpredictable pain that are caused by vaso-occlusive crises (VOCs), a hallmark of the disease. VOCs are the primary cause of hospitalization in SCD, result in missed workdays and school days, and decrease quality of life (QoL). Although VOCs cause significant burden in the lives of individuals with SCD, there is no synthesis on the frequency of VOCs in the real world. This systematic literature review sought to identify literature describing the frequency of VOCs experienced by individuals with SCD in real-world settings. METHODS MEDLINE and 6 congresses were searched (date range: January 1, 2000 to June 30, 2020). Studies were reviewed independently by two researchers. Studies assessing frequency or prevalence of VOCs or VOC-related outcomes were included. RESULTS Of 1438 studies identified in the search, 52 met pre-specified inclusion and exclusion criteria. Reported frequency of VOCs varied widely ranging from a mean or median of 0 VOCs/year to 18.2 VOCs/year. The proportion of patients experiencing ≥ 3 VOCs/year ranged from 4 to 67% and the proportion of patients experiencing ≥ 5 VOCs/year ranged from 18 to 59%. Measures of VOC severity were limited, with 13 studies considering frequency of complicated VOCs and only 1 study reporting duration of VOC episodes. CONCLUSIONS This is the first study to systematically assess published evidence pertaining to VOCs in real-world settings. Reported VOC frequency in real-world settings varied widely, with a majority of studies only considering VOCs managed in an inpatient or outpatient setting. Studies that considered VOCs managed at home reported a higher frequency of VOCs, suggesting that many studies may underestimate the frequency of VOCs. This systematic literature review (SLR) highlights the need for consistent reporting of (1) self-reported VOCs, including those managed at home, (2) definitions of VOCs, (3) complicated VOCs, and (4) duration of VOC episodes in literature.
3.
Perioperative blood transfusion is associated with worse clinical outcomes in resected lung cancer
Wang T, Luo L, Huang H, Yu J, Pan C, Cai X, Hu B, Yin X
Annals of Thoracic Surgery. 2014;97((5):):1827-37.
Abstract
The deleterious effect of perioperative allogeneic blood transfusion in patients with resected lung cancer has been controversial. We conducted this meta-analysis to answer the question of whether perioperative allogeneic blood transfusion adversely affects recurrence and survival in patients with resected lung cancer. Included were 23 studies with 6,474 patients. The result showed allogeneic blood transfusion was significantly associated with earlier recurrence and worse survival in patients with surgically resected lung cancer. We suggest transfusion policy should be stricter in lung cancer patients undergoing resection, especially with early-stage disease. Prospective large-scale studies are still warranted. Copyright 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.